ArticleFrontiers in pharmacology2019
The Impact of Ayahuasca on Suicidality: Results From a Randomized Controlled Trial.
Article in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2023Pooled it
- Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants.Psychopharmacology · 2021Pooled it
- Enhancing mindfulness and compassion through an ayahuasca-inspired formulation containing N,N-DMT and harmine: A randomized controlled trial in healthy subjects.Journal of psychopharmacology (Oxford, England) · 2026Trial
- Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Trial
- Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial.Psychopharmacology · 2021Trial
- Registered Clinical Trials of Ayahuasca and DMT: A Scoping Review.Clinical pharmacology and therapeutics · 2026Article
- New Antidepressant Development in the Treatment of Depression.Advances in experimental medicine and biology · 2026Review
- Psilocybin and ayahuasca in treatment-resistant depression: clinical evidence, methodological constraints and ethical challenges: a narrative review.Frontiers in psychiatry · 2026Review
- Inhaled N, N-dimethyltryptamine diminishes connectivity between the ventral tegmental area and the nucleus accumbens: relevance to pathologies of mesolimbic and mesocortical pathways.Scientific reports · 2025Article
- Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties.Psychopharmacology · 2025Review
- Psychedelic Drugs in Mental Disorders: Current Clinical Scope and Deep Learning-Based Advanced Perspectives.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Psychedelics and Suicide-Related Outcomes: A Systematic Review.Journal of clinical medicine · 2025Review
- Neurobiological substrates of altered states of consciousness induced by high ventilation breathwork accompanied by music.PloS one · 2025Article
- Towards culturally inclusive healthcare in Peru: Mapping epistemic concepts in contemporary Indigenous Amazonian medicine-Traditional healers' perspectives.PLOS global public health · 2025Article
- Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors.Cellular and molecular life sciences : CMLS · 2024Review
- Epigenetic mechanisms of rapid-acting antidepressants.Translational psychiatry · 2024Review
- Review
- Psychiatric risks for worsened mental health after psychedelic use.Journal of psychopharmacology (Oxford, England) · 2024Review
- Long-term benefits to psychological health and well-being after ceremonial use of Ayahuasca in Middle Eastern and North African immigrants and refugees.Frontiers in psychiatry · 2024Article
- Longitudinal and transcultural assessment of the relationship between hallucinogens, well-being, and post-traumatic growth during the COVID-19 pandemic.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Suicide is a major public health problem. Given increasing suicide rates and limitations surrounding current interventions, there is an urgent need for innovative interventions for suicidality. Although ayahuasca has been shown to target mental health concerns associated with suicidality (i.e., depression and hopelessness), research has not yet explored the impact of ayahuasca on suicidality. Therefore, we conducted secondary analyses of a randomized placebo-controlled trial in which individuals with treatment-resistant depression were administered one dose of ayahuasca (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.